Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Expands bioprocessing footprint across Asia
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The center will offer training to super-specialist doctors and healthcare professionals in various fields
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Subscribe To Our Newsletter & Stay Updated